Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Go back to Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.11 -0.78 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.89 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $153.23 | P/E | 82.93 | |||
| Day Low | $149.57 | EPS | $1.81 | |||
| Volume | 16,443,951 | |||||
